Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessResearch

The Economic impact of ME/CFS: Individual and societal costs

Leonard A Jason1 email, Mary C Benton2 email, Lisa Valentine3 email, Abra Johnson1 email and Susan Torres-Harding4 email

1Department of Psychology, Depaul University, Center for Community Research, Chicago, IL, USA

2Department of Psychology, Wichita State University, Wichita, KS, USA

3Department of Psychology, University of North Texas, Denton, TX, USA

4Department of Psychology, Roosevelt University, Chicago, IL, USA

author email corresponding author email

Dynamic Medicine 2008, 7:6doi:10.1186/1476-5918-7-6

Published: 8 April 2008

Abstract

Background

ME/CFS is characterized by debilitating fatigue in addition to other physical and cognitive symptoms. It is estimated to affect over 800,000 adults in the U.S. ME/CFS often results in diminished functionality and increased economic impact. The economic impact of an illness is generally divided into two categories: direct and indirect costs. Despite high prevalence rates and the disabling nature of the illness, few studies have examined the costs of ME/CFS at the individual and societal level. In fact, of the four studies examining the economic impact of ME/ME/CFS only two used a U. S. sample. The current study used community and tertiary samples to examine the direct costs of ME/CFS.

Methods

Using archival data, Study 1 examined the direct cost of ME/CFS in a community-based sample in Chicago. Study 2 estimated the direct cost of ME/CFS in a tertiary sample in Chicago. Both Study1 and Study 2 assessed direct costs using office visit costs, medical test costs, and medication costs.

Results

For Study 1, the annual direct total cost per ME/CFS patient was estimated to be $2,342, with the total annual direct cost of ME/CFS to society being approximately $2 billion. In Study 2, the annual direct was estimated to be $8,675 per ME/CFS patient, with the total annual direct cost of ME/CFS to society being approximately $7 billion.

Conclusion

Using ME/CFS prevalence data of 0.42 and indirect costs estimates from Reynolds et al. (2004), the direct and indirect cost of ME/CFS to society was estimated to be $18,677,912,000 for the community sample and $23,972,300,000 for the tertiary sample. These findings indicate that whether or not individuals are recruited from a community or tertiary sample, ME/CFS imposes substantial economic costs.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.